News

February 23, 2016

LeafBio Announces Conclusion of ZMapp™ Clinical Trial

 

February 27, 2015

LeafBio Announces Acceptance of Investigational New Drug Application for Ebola Therapy ZMapp™

 

February 6, 2015

LeafBio Submits Investigational New Drug Application for Lead Product Candidate ZMapp™ for the Treatment of Ebola Virus Infection

 

August 6, 2014

Defyrus Inc. and H&P Labs Inc. enter into a Collaboration and Licensing Agreement on DEF201

 

August 4, 2014

ZMapp Information Sheet

 

July 15, 2014

Monoclonal Antibody-based Filovirus Therapeutic Licensed to Leaf Biopharmaceutical

 

July 29, 2013

International Joint Venture to Drive Commercialization of Filovirus Therapeutic via Monoclonal Antibodies

 

March 22, 2013

Minister Toews Announces Investments in Manitoba Projects to Enhance Canada's Safety and Security

 

October 4, 2012

US Patent and Trademark Office Allows Patent on Defyrus’ Breakthrough Broad Spectrum Antiviral Drug (DEF201)

 

June 13, 2012

Ebola-specific monoclonal combination drug “ZMAb” extends treatment window to >1 day, study results published in Science Translational Medicine

 

March 28, 2012

NIAID completes pilot DEF201 safety and toxicology study at SRI International

 

November 15, 2011

Defilovir™ is an effective treatment against Ebola virus infection in two animal models; study results published in Journal of Bioterrorism & Biodefense

 

March 11, 2011

US Army and Defyrus sign Collaborative R&D Agreement

 

March 4, 2011

Defyrus Expands Antiviral Testing with the National Institute of Allergy and Infectious Diseases (NIAID) to Include Testing Against 5 Additional Pathogenic Viruses

 

Jan. 1, 2011

AdVec Inc. Licenses Adenoviral Vectors and Manufacturing Patent Portfolio to Defyrus Inc

 

Dec. 16, 2010

Defyrus international patent application entitled “Administration of interferon for prophylaxis against or treatment of pathogenic infection” PCT/CA2010/000844 published

 

April 16, 2010

Pilot Manufacturing Contract Signed with Robert Fitzhenry Vector Laboratory, McMaster University

 

March 29, 2010

Defyrus and NML sign CRA to jointly pursue R&D on adenovirus vectored vaccines and broad spectrum antivirals

 

Oct. 23, 2009

Defyrus Completes Secondary Equity Financing

 

Aug. 2, 2009

Dr. Jack Gauldie and Mr. John Hyshka Join Defyrus Board of Directors

 

Mar. 12, 2009

Defyrus & U.S. Department of Health and Human Services Sign Non-Clinical Evaluation Agreement

 

Feb. 19, 2009

Vaccine Patent Portfolio Licensed from UK Ministry of Defence

 

Oct. 23, 2008

Defyrus completes equity financing raising $3.1 million

 

Sept. 19, 2008

Defyrus & DRDC sign Memorandum of Understanding to cooperate on biodefence R&D